Natural Cycles, a Stockholm-based women’s health company, has secured €50.8 million in Series C funding led by Lauxera Capital Partners, with additional participation from Point72 Private Investments and a revolving debt facility from J.P. Morgan. This latest investment aims to enhance commercial growth, product innovation, and streamline healthcare reimbursement automation. Co-founded in 2013 by Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, Natural Cycles developed the first FDA-cleared digital contraceptive used by over three million women worldwide. The company recently introduced NC° Postpartum, expanding its app’s support to new mothers and underscoring its commitment to providing comprehensive hormone-free birth control options.
Founded in 2013 by Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, Natural Cycles developed the first direct-to-consumer contraceptive app that has been used by more than three million users worldwide. It remains the only digital form of birth control on the market cleared by regulators in the United States (FDA), Europe (TÜV SÜD), Canada (Health Canada), Australia (TGA), Singapore (HSA), and South Korea (MFDS).
“We’ve experienced profitable growth over the last few years as women actively seek more birth control options and we’re excited to welcome the next phase of Natural Cycles journey together with Lauxera Capital Partners and Point72 Private Investments,” said Dr. Raoul Scherwitzl, co-founder and CEO of Natural Cycles. “We look forward to leveraging their expertise to fulfill Natural Cycles’ mission of making hormone-free birth control more accessible and combining technology and science to fill the gaps in underserved areas of women’s health.”
Earlier this month Natural Cycles launched NC° Postpartum, an innovative experience within the Natural Cycles app specifically tailored to help guide new moms recovering physically and mentally from childbirth. NC° Postpartum builds on the other three modes already available within the Natural Cycles app – NC° Birth Control, NC° Plan Pregnancy, and NC° Follow Pregnancy – providing users with support throughout their fertility journey.
“Our mission at Lauxera is to partner with ambitious entrepreneurs transforming the future of medicine with unique technology. The visionary Natural Cycles team has built an exceptional company delivering profitable growth supported by unique clinical and regulatory business moats,” added Samuel Levy, founding partner of Lauxera Capital Partners. “We are delighted to partner with Elina, Raoul and their team to offer women an alternative to traditional approaches without the side effects and compromises.”
As part of the investment, Levy will join Natural Cycles’ Board of Directors. Lauxera Capital Partners and Point72 Private Investments join Natural Cycles’ current distinguished investors, which include EQT Ventures, Samsung Ventures, Heartcore Capital, Headline, and Bonnier Ventures.
Click to read more funding news.
